The Impact of the HeLa Cell in the Field of Otolaryngology: Honoring Henrietta Lacks
Open Access
- 22 October 2026
- journal article
- review article
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 11 (5) , e70593
Abstract
Introduction: The HeLa cell, which was first taken from Henrietta Lacks in 1952, was the first in vitro cell line discovered and propagated in mass. From polio vaccine development to understanding cancer biology, the HeLa cell has allowed for immeasurable scientific advances. No prior review has examined how the HeLa cell has influenced the field of otolaryngology. Methods: A PRISMA‐style approach was taken in this narrative literature review to understand the historical context of the human papilloma virus (HPV) and how the HeLa cell elucidated HPV‐mediated cancers. Then, using MeSH terminology, each subspecialty of otolaryngology (i.e., head and neck cancer, audiology, otology, rhinology, and laryngology) was used to identify studies that incorporated HeLa cells to understand how HeLa cells made direct impacts on otolaryngology research. Results: The HeLa cell was crucial to identifying how HPV causes tumorigenesis, and due to enhanced cervical cancer knowledge, this boosted head and neck tumor discoveries. Basic biology, such as how cisplatin functions, which is now a common chemotherapeutic used for head and neck cancer, was studied using the HeLa cell line. Due to the cells' reliable, accessible, and rapidly dividing characteristics, the HeLa cell was also used broadly in hearing and sensory research. Discussion: Although the HeLa cell line comes with great bioethical controversy, the HeLa cell has improved the lives of countless people. It is important to consider the lives of historically underserved communities and individuals, such as Henrietta Lacks, to both honor and recognize the contributions diverse people from every racial and economic background make to science.Keywords
This publication has 76 references indexed in Scilit:
- Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-2045JAMA Oncology, 2021
- Koilocytic changes are not elicited by human papillomavirus genotypes with higher oncogenic potentialJournal of Medical Virology, 2020
- HEI-OC1 cells as a model for investigating drug cytotoxicityHearing Research, 2016
- Critical link between glycogen synthase kinase 3β and forkhead box P3 in patients with chronic rhinosinusitis with nasal polypsJournal of Allergy and Clinical Immunology, 2015
- Establishment and characterization of a novel HPV-negative laryngeal squamous cell carcinoma cell line, FD-LSC-1, with missense and nonsense mutations of TP53 in the DNA-binding domainCancer Letters, 2013
- Activation of apoptotic pathways in the absence of cell death in an inner-ear immortomouse cell lineHearing Research, 2011
- Rhinosinusitis: Developing guidance for clinical trialsJournal of Allergy and Clinical Immunology, 2006
- Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric scFvs blocks the E6-mediated degradation of cellular p53Journal of Molecular Recognition, 1999
- Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNAInternational Journal of Cancer, 1982
- Partial characterization of viral DNA from human genital warts (condylomata acuminata)International Journal of Cancer, 1980